Serum Levels of Plasminogen Activator Inhibitor-1 in Patients with Parkinson's Disease.

IF 2.9 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Medical Principles and Practice Pub Date : 2024-01-01 Epub Date: 2024-08-12 DOI:10.1159/000540854

Azra Meryem Tanrikulu, Betul Ozdilek, Mehmet Agirbasli

{"title":"Serum Levels of Plasminogen Activator Inhibitor-1 in Patients with Parkinson's Disease.","authors":"Azra Meryem Tanrikulu, Betul Ozdilek, Mehmet Agirbasli","doi":"10.1159/000540854","DOIUrl":null,"url":null,"abstract":"Objectives: The aim of the study was to investigate serum plasminogen activator inhibitor-1 (PAI-1) levels of patients with Parkinson's disease (PD) and their relationship with clinical findings and treatment of disease.Methods: The study included 125 PD patients and 48 healthy controls. Patients have been taking effective dopaminergic treatment regularly. The clinical severity of parkinsonism was assessed using the Hoehn and Yahr (HY) staging scale and the Unified PD Rating Scale (UPDRS). PAI-1 level analysis was performed by enzyme-linked immunosorbent assay.Results: Patients with PD had significantly lower serum PAI-1 levels than healthy controls (p < 0.001). Correlations with clinical findings showed only a marginally positive correlation between serum PAI-1 and HY score (r = 0.170, p = 0.05). In contrast, no significant correlation was demonstrated with the UPDRS score or other clinical parameters.Conclusion: This is the first comprehensive analysis of serum PAI-1 levels in patients with PD. The distribution of PAI-1 in PD appears to be complex. The study results implicate that the paradoxical effects of tissue plasminogen activator on the brain parenchyma can be important in the pathophysiology of PD. Future studies are needed to elucidate the role of fibrinolytic system components in PD.","PeriodicalId":18455,"journal":{"name":"Medical Principles and Practice","volume":" ","pages":"562-568"},"PeriodicalIF":2.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11631035/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Principles and Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540854","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The aim of the study was to investigate serum plasminogen activator inhibitor-1 (PAI-1) levels of patients with Parkinson's disease (PD) and their relationship with clinical findings and treatment of disease.

Methods: The study included 125 PD patients and 48 healthy controls. Patients have been taking effective dopaminergic treatment regularly. The clinical severity of parkinsonism was assessed using the Hoehn and Yahr (HY) staging scale and the Unified PD Rating Scale (UPDRS). PAI-1 level analysis was performed by enzyme-linked immunosorbent assay.

Results: Patients with PD had significantly lower serum PAI-1 levels than healthy controls (p < 0.001). Correlations with clinical findings showed only a marginally positive correlation between serum PAI-1 and HY score (r = 0.170, p = 0.05). In contrast, no significant correlation was demonstrated with the UPDRS score or other clinical parameters.

Conclusion: This is the first comprehensive analysis of serum PAI-1 levels in patients with PD. The distribution of PAI-1 in PD appears to be complex. The study results implicate that the paradoxical effects of tissue plasminogen activator on the brain parenchyma can be important in the pathophysiology of PD. Future studies are needed to elucidate the role of fibrinolytic system components in PD.

查看原文本刊更多论文

帕金森病患者血清中血浆蛋白酶原激活剂抑制剂-1 的水平。

目的研究帕金森病（PD）患者的血清纤溶酶原激活物抑制剂-1（PAI-1）水平及其与临床表现和疾病治疗的关系：研究对象包括 125 名帕金森病患者和 48 名健康对照者。患者均定期接受有效的多巴胺能治疗。采用 Hoehn 和 Yahr（HY）分期量表和统一帕金森病评分量表（UPDRS）评估帕金森病的临床严重程度。PAI-1水平分析采用酶联免疫吸附测定法进行：结果：PD 患者的血清 PAI-1 水平明显低于健康对照组（p < 0.001）。与临床结果的相关性显示，血清 PAI-1 与 HY 评分之间仅有轻微的正相关性（r = 0.170，p = 0.05）。相比之下，血清 PAI-1 与 UPDRS 评分或其他临床参数无明显相关性：这是首次对 PD 患者血清 PAI-1 水平进行全面分析。PAI-1在帕金森病中的分布似乎很复杂。研究结果表明，组织纤溶酶原激活剂对脑实质的矛盾作用可能是帕金森病病理生理学的重要因素。未来的研究需要阐明纤溶系统成分在帕金森病中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Principles and Practice 医学-医学：内科

CiteScore

6.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Medical Principles and Practice'', as the journal of the Health Sciences Centre, Kuwait University, aims to be a publication of international repute that will be a medium for dissemination and exchange of scientific knowledge in the health sciences.